High-dose-rate brachytherapy combined with long-term hormonal therapy for high-risk prostate cancer: Results of a retrospective analysis
Tóm tắt
High-dose-rate (HDR) brachytherapy combined with hormonal therapy (HTx), without the addition of external beam radiation therapy (EBRT) for high-risk prostate cancer was evaluated retrospectively. Between May 1995 and April 2002, 35 patients with prostate cancer [Stage≥T2b (UICC 1997) or tumor grading=3 or prostate-specific antigen (PSA) level≥20 ng/mL] were treated with HDR brachytherapy combined with HTx. Most patients (74%) had two or more of these factors. All patients received Iridium-192 HDR brachytherapy with a total dose of 54 Gy/9 fractions/5 days (48 Gy/8 fractions/5 days for the first 6 cases) in one implant session. The median neoadjuvant HTx [luteinizing hormone-releasing hormone (LH-RH) agonist and antiandrogen] period was 7 months. The median adjuvant HTx (ATH) (LH-RH agonist) period was 40 months, and median follow-up was 57 months (range, 23–117 months). The 5-year actuarial biochemical control, local control, and disease-free rates were 62%, 96%, and 76% respectively. No patients experienced local and/or regional relapse without distant progression. The 5-year actuarial cause-specific survival and overall survival rates were 89% and 87%, respectively. The acute and late toxicity were moderate and well tolerated. HDR brachytherapy plus long-term HTx is at least as effective as conventional EBRT plus long-term HTx.
Tài liệu tham khảo
Bolla M, Gonzalez D, Warde P,et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin.N Engl J Med, 337:295–300, 1997.
Hanks GE, Pajak TF, Porter A,et al. Phase III trial of long-term adjuvant androgen deprivation after neo-adjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02.J Clin Oncol, 21: 3972–3978, 2003.
Pilepich MV, Caplan R, Byhardt RW,et al. Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31.J Clin Oncol, 15: 1013–1021, 1997.
Pilepich MV, Winter K, John MJ,et al. Phase III Radiation Therapy Oncology Group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate.Int J Radiat Oncol Biol Phys, 50: 1243–1252, 2001.
Bolla M, Collette, L, Blank L,et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomized trial.Lancet, 360: 103–106, 2002.
Roach M 3rd, DeSilvio M, Lawton C,et al. Phase III trial comparing whole-pelvic versus prostate-only radio-therapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 94-13.J Clin Oncol, 21: 1904–1911, 2003.
Roach M 3rd, Lu J, Pilepich MV, et al. Predicting long term-survival, and the need for hormonal therapy: a meta-analysis of RTOG prostate cancer trials.Int J Radiat Oncol Biol Phys, 47: 617–627, 2000.
Perez CA, Lee HK, Georgiou A, Lockett MA. Technical factors affecting morbidity in definitive irradiation for localized carcinoma of the prostate.Int J Radiat Oncol Biol Phys, 28: 811–819, 1994.
Malone S, Crook JM, Kendal WS, Szanto J. Respiratory-induced prostate motion: quantification and characterization.Int J Radiat Oncol Biol Phys, 48: 105–109, 2000.
Vigneault E, Pouliot J, Laverdiere J, Roy J, Dorion M. Electronic portal imaging device detection of radioopaque markers for the evaluation of prostate position during megavoltage irradiation: a clinical study.Int J Radiat Oncol Biol Phys, 37: 205–212, 1997.
Mostofi FK. Grading of prostatic carcinoma.Cancer Chemother Rep, 59: 111–117, 1975.
TNM classification of malignant tumors (UICC), 5th ed. (Sobin LH, Wittekind C eds.; Springer, New York), 1997.
Yoshioka Y, Nose T, Yoshida K, et al. High-dose-rate interstitial brachytherapy as a monotherapy for localized prostate cancer: treatment description and preliminary results of a phase I/II clinical trial.Int J Radiat Oncol Biol Phys, 48: 675–681, 2000.
Yoshioka Y, Nose T, Yoshida K, et al. High-dose-rate brachytherapy as a monotherapy for localized prostate cancer: a retrospective analysis with special focus on tolerance and chronic toxicity.Int J Radiat Oncol Biol Phys, 56: 213–220, 2003.
Consensus statement: guidelines for PSA following radiation therapy. American Society for Therapeutic Radiology and Oncology Consensus Panel.Int J Radiat Oncol Biol Phys, 37: 1035–1041, 1997.
Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC).Int J Radiat Oncol Biol Phys, 31: 1341–1346, 1995.
Kaplan EL, Meier P. Nonparametric estimation from incomplete observations.J Amer Statist Assn, 53: 457–481, 1958.
Vicini FA, Martinez A, Hanks G,et al. An interinstitutional and interspecialty comparison of treatment outcome data for patients with prostate carcinoma based on predefined prognostic categories and minimum follow-up.Cancer, 95: 2126–2135, 2002.
Seaward S, Weinberg V, Lewis P,et al. Improved freedom from PSA failure with whole pelvic irradiation for high-risk prostate cancer.Int J Radiat Oncol Biol Phys, 42: 1055–1062, 1998.
Hanks GE, Hanlon AL, Pinover WH, Horwitz EM, Price RA, Schultheiss T. Dose selection for prostate cancer patients based on dose comparison and dose response studies.Int J Radiat Oncol Biol Phys, 46: 823–832, 2000.
Pollack A, Zagars GK. External beam radiotherapy dose response of prostate cancer.Int J Radiat Oncol Biol Phys, 39: 1011–1018, 1997.
Brenner DJ, Hall EJ. Fractionation and protraction for radiotherapy of prostate carcinoma.Int J Radiat. Oncol Biol Phys, 43: 1095–1101, 1999.
Fowler JF. The linear-quadratic formula and progress in fractionated radiotherapy.Br J Radiol, 62: 679–694, 1989.
Brenner DJ, Hall EJ. Fractionation and protraction for radiotherapy of prostate carcinoma.Int J Radiat Oncol Biol Phys, 43: 1095–1101, 1999.
Martinez AA, Pataki I, Edmundson G, Sebastain E, Brabbins D, Gustafson G. Phase II prospective study of the use of conformal high-dose-rate brachytherapy as monotherapy for the treatment of favorable stage prostate cancer: a feasibility report.Int J Radiat Oncol Biol Phys, 49: 61–69, 2001.
Duchesne GM, Peter LJ. What is the alpha/beta ratio for prostate cancer? Rationale for hypofractionated highdose-rate brachytherapy.Int J Radiat Oncol Biol Phys, 44: 747–748, 1999.
Seaward SA, Weinberg V, Lewis P, Leigh B, Phillips TL, Roach M 3rd. Identification of a high-risk clinically localized prostate cancer subgroup receiving maximum benefit from whole-pelvic irradiation.Cancer J Sci Am, 4: 370–377, 1998.
Mameghan H, Fisher R, Mameghan J, Watt WH, Tynan A. Bowel complications after radiotherapy for carcinoma of the prostate: the volume effect.Int J Radiat Oncol Biol Phys, 18: 315–320, 1990.
Ray GR, Cassady JR, Bagshaw MA. Definitive radiation therapy of carcinoma of the prostate. A report on 15 years of experience.Radiology, 106: 407–418, 1973.
Pilepich MV, Perez CA, Walz BJ, Zivnuska FR. Complications of definitive radiotherapy for carcinoma of the prostate.Int J Radiat Oncol Biol Phys, 7:1341–1348, 1981.
Leibel SA, Hanks GE, Kramer S. Patterns of care outcome studies: results of the national practice in adenocarcinoma of the prostate.Int J Radiat Oncol Biol Phys, 10: 401–409. 1984.
Zagars GK, von Eschenbach AC, Johnson DE, Oswald MJ. Stage C adenocarcinoma of the prostate. An analysis of 551 patients treated with external beam radiation.Cancer, 60: 1489–1499, 1987.